Department of Otorhinolaryngology, Nippon Medical School Tamanagayama Hospital, Tokyo, Japan; Department of Otorhinolaryngology, Nippon Medical School, Tokyo, Japan.
Department of Disease Model, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Allergol Int. 2024 Oct;73(4):494-500. doi: 10.1016/j.alit.2024.07.001. Epub 2024 Jul 22.
In 2004, we started the initial attempt to evaluate the efficacy of SLIT for Japanese cedar pollinosis (JCP) using Japanese cedar (JC) pollen extract solution through a multicenter, placebo-controlled, double-blind comparative study. Based on its success in demonstrating the substantial efficacy of SLIT, we next conducted a larger-scale study by administering JC pollen to all JCP patients recruited. It was because of aiming to ascertain the effectiveness and safety of SLIT and its underlying mechanisms by comparing high- and non-responder patients. Despite limitations posed by liquid medication, significant effectiveness and safety demonstrated by the 2-year treatment served as the foundation for launching the first SLIT medicine for JCP, in 2014. Furthermore, in addition to the clearer Th1/Th2-imbalanced property in the high-responders, the possible involvement of bitter taste receptors in CD4 T cells, apoptosis pathways in CD4 T cells and basophils, and inducing a mast cell degranulation inhibitory molecule in the effect of SLIT was demonstrated. To solve the limitations posed by liquid medication, clinical trials evaluating JC pollen sublingual tablets started in 2014. Due to the minimal side effects, ease of administration, and convenient storage, the sublingual tablet medicine was launched in 2018. Giving the ongoing rise in demand for SLIT and considering that more than 1% of JCP patients are currently undergoing SLIT, the practical use of this treatment for multiple allergens is becoming increasingly important.
2004 年，我们开始通过多中心、安慰剂对照、双盲比较研究，首次尝试使用日本扁柏花粉提取物溶液评估 SLIT 治疗日本柏花粉过敏症（JCP）的疗效。在此项研究成功证实 SLIT 具有显著疗效的基础上，我们接下来对所有招募的 JCP 患者进行了更大规模的研究，给予日本扁柏花粉。之所以旨在通过比较高反应者和非反应者来确定 SLIT 的有效性和安全性及其潜在机制，是因为它旨在确定 SLIT 的有效性和安全性及其潜在机制。尽管受到液体药物的限制，但 2 年治疗的显著效果和安全性为 2014 年推出首个 JCP SLIT 药物奠定了基础。此外，除了高反应者中更明显的 Th1/Th2 失衡特性外，还证明了苦味受体在 CD4 T 细胞、CD4 T 细胞和嗜碱性粒细胞中的凋亡途径以及诱导 SLIT 效应中的肥大细胞脱颗粒抑制分子的可能参与。为了解决液体药物带来的限制，自 2014 年开始评估日本扁柏花粉舌下片剂的临床试验。由于副作用极小、给药方便、储存方便，2018 年推出了舌下片剂药物。鉴于 SLIT 的需求持续增长，考虑到目前有超过 1%的 JCP 患者正在接受 SLIT，这种治疗方法对多种变应原的实际应用变得越来越重要。
